Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* A male or female child between 18 months and 4 years of age (up to but not including 5th birthday) at the time of first vaccination.~* Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits)~Exclusion criteria:~* Acute disease at the time of enrolment.~* Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.~* Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of range.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid.~* Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Previous participation in any other malaria vaccine trial.~* Simultaneous participation in any other clinical trial.~* Same sex twin.~* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 48 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): None
- Group B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).